Principal Investigator
Craig Surman, MD
Massachusetts General Hospital
- 4 trials
- 1 compound
Therapeutic focus
- Attention Deficit Hyperactivity Disorder
- Attention Deficit/Hyperactivity Disorder
- ADHD
- Attention Deficit Hyperactivity Disorder (ADHD)
- Deficient Emotional Self-Regulation (DESR)
All trials (4)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT04839562 | Phase 2/3 | Completed | Solriamfetol (Sunosi) | Axsome Therapeutics, Inc. |
| NCT02558790 | Phase 2 | Completed | — | Massachusetts General Hospital |
| NCT01853280 | Phase 2/3 | Completed | — | Massachusetts General Hospital |
| NCT01399827 | Phase 2 | Completed | — | Massachusetts General Hospital |
Compounds studied
Trial sites (1)
- Boston, Massachusetts, United States
Investigator and site data mirrored fromClinicalTrials.gov (public domain).